Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|March 10, 2015
SAH derived potent and selective EZH2 inhibitorsPei-Pei Kung, Buwen Huang, Luke Zehnder, et al.Journal of Medicinal Chemistry|February 2, 2021
Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate ProdrugPei-Pei Kung, Connie Fan, Hovhannes J Gukasyan, et al.Journal of Medicinal Chemistry|March 29, 2011
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamideLuke Zehnder, Michael Bennett, Jerry Meng, et al.Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.Journal of Medicinal Chemistry|August 12, 2016
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.Journal of Medicinal Chemistry|December 7, 2017
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)Pei-Pei Kung, Patrick Bingham, Alexei Brooun, et al.Pageof 1